Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BB 882; DO 6; GR 167089; Lexipafant - Vernalis; Zacutex

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer DevCo Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antiplatelets; Branched-chain amino acids; Imidazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Platelet activating factor inhibitors; Platelet activating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cognition disorders; Neurological disorders; Pancreatitis; Reperfusion injury
  • Discontinued Arrhythmias; Asthma; Ischaemic heart disorders; Multiple sclerosis

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 23 Mar 2004 Lexipafant is available for licensing (http://www.devcopharma.com)
  • 23 Mar 2004 Clinical data from a media release have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top